96976 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons; Interleukins [IL] IL-2
TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS
#2COMBINATION THERAPIES USING MOLECULES BINDING TO TCR
#3PHARMACEUTICAL COMPOSITION CONTAINING FUSION PROTEIN
#4ONCOSELECTIVE THERAPY
#5MODIFIED MAMMALIAN VESICLES AND COMPOSITIONS AND METHODS RELATED THERETO
#6MASKED CYTOKINE POLYPEPTIDES
#7CELL SIGNALING COMPLEXES AND USES THEREOF
#8T-Cell Modulatory Polypeptides and Methods of Use Thereof
#9Conjugate Comprising an IL-2 Moiety
#10BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS
#11METHODS FOR REPROGRAMMING AND GENE EDITING CELLS
#12IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS
#13IMMUNOTOXIN-BASED TARGETED THERAPY FOR CANCER
#14FUSIONS WITH CD8 ANTIGEN BINDING MOLECULES FOR TREATING CHRONIC VIRAL INFECTION
#15INTERLEUKIN-2 FOR USE IN TREATING AUTISM SPECTRUM DISORDER
#16Recombinant Fc domain - IL2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
#17HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#18TISSUE SPECIFIC SYNTHETIC PROMOTERS AND CIRCUITS AND USE THEREOF
#19ANTI-PD-1 ANTIBODY-ATTENUATED IL-2 IMMUNOCONJUGATE FORMULATIONS
#20IMMUNOCONJUGATES
#21Enhanced adoptive cell therapy
#22MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
#23T-Cell Modulatory Chimeric Molecules and Methods of Use Thereof
#24FUSION PROTEIN COMPRISING ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOF
#25INTERLEUKIN-2 MUTANT AND FUSION PROTEIN THEREOF
#26KINASE MUTANTS AND USES THEREOF
#27T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof
#28METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES
#29BISPECIFIC IMMUNOTOXINS TARGETING HUMAN CD25+CCR4+ TUMORS AND REGULATORY T-CELLS
#30ENGINEERED PROTEINS TO ENHANCE SENSITIVITY OF A CELL TO IL-2
#31T CELL EPITOPES ASSOCIATED WITH TYPE 1 DIABETES
#32HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#33IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES
#34HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#35USE OF IL-2 VARIANT FOR TREATING KIDNEY TRANSPLANT REJECTION
#36INTERLEUKIN-2 VARIANTS AND THEIR USES IN TREATING CANCERS
#37METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG
#38Non-Signaling Chimeric Antigen Receptor Gamma Delta T-Cells
#39MASKED IL-2 CYTOKINES AND METHODS OF USE THEREOF
#40THERAPEUTIC CYTOKINES AND METHODS
#41METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES
#42METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
#43COMPOSITIONS AND METHODS FOR IMPROVED NK CELL THERAPIES
#44USES AND METHODS FOR IL-2, IL-13, AND IL-4 CYTOKINE BIFUNCTIONAL MOLECULES
#45Il-2 Mutants And Uses Thereof
#46Safety Kill Switches for Engineered Cells Carrying Synthetic Chromosomes
#47T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof
#48USE of Antibody Mutation FOR Therapeutic Antibody Drug
#49BIFUNCTIONAL IL-2 AND IL-10 FUSION PROTEINS AND USES THEREOF
#50NEO-2/15 Variants and Uses Thereof for Preferentially Stimulating T-Regulatory Cells
#51FUSION PROTEIN FOR MAINTENANCE OF REGULATORY T-CELLS
#52IMMUNORECEPTOR INHIBITORY PROTEINS AND RELATED METHODS
#53NOVEL ANTIBODY-CYTOKINE FUSION PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOF
#54ANTI-PD-L1 MONOCLONAL ANTIBODIES AND FUSION PROTEINS WITH INTERLEUKIN-15, INTERLEUKIN-15 RECEPTOR ALPHA, OR INTERLEUKIN-2
#55COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN BINDING MOLECULES
#56TETHERED INTERLEUKIN-2 RECOMBINANT RECEPTORS AND METHODS OF USE
#57FUSION PROTEIN OF ANTI-TIGIT ANTIBODY AND IL2 OR VARIANT THEREOF, AND APPLICATION THEREOF
#58METHODS TO GENERATE ENHANCED TUMOR INFILTRATING LYMPHOCYTES THROUGH MICROFLUIDIC DELIVERY
#59ENGINEERED INTERLEUKIN-2 RECEPTOR BETA REDUCED-BINDING AGONIST
#60CYTOKINE-BASED BIOACTIVATABLE DRUGS AND METHODS OF USES THEREOF
#61CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
#62CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
#63BLOCKADE OF CD3 EXPRESSION AND CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY
#64CD8-Binding Polypeptides and Uses Thereof
#65Primary NK CAR Constructs And Methods
#66CONJUGATES OF AN IL-2 MOIETY AND A POLYMER
#67MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF
#68MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF
#69ENHANCED ANTIGEN PRESENTING ABILITY OF CAR T CELLS BY CO-INTRODUCTION OF COSTIMULATORY MOLECULES
#70CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY
#71IL-2 VARIANTS WITH REDUCED BINDING TO IL-2 RECEPTOR ALPHA AND USES THEREOF
#72HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS)
#73ELIMINATION OF CD19-POSITIVE LYMPHOID MALIGNANCIES BY CD19-CAR EXPRESSING NK CELLS
#74METHODS OF TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS
#75METHODS OF TREATING GRAFT VERSUS HOST DISEASE USING IL-2 MUTEINS
#76IMMUNE CELL INHIBITION BY IMMUNE CHECKPOINT ENGAGERS
#77BIFUNCTIONAL MOLECULE FORMED BY FUSION OF PD1 ANTIBODY AND INTERLEUKIN 2
#78VECTORS, GENETICALLY MODIFIED CELLS, AND GENETICALLY MODIFIED NON-HUMAN ANIMALS COMPRISING THE SAME
#79MASKED IL-2 CYTOKINES AND METHODS OF USE THEREOF
#80CYTOKINE ENGAGERS AND USES THEREOF
#81CAR-EXPRESSING CELLS AGAINST MULTIPLE TUMOR ANTIGENS AND USES THEREOF
#82Interleukin-2 Polypeptides, Fusion Polypeptides, and Methods of Use Thereof
#83T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof
#84CHIMERIC ANTIGEN RECEPTOR MODIFIED REGULATORY T CELLS FOR TREATING CANCER
#85HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#86FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF
#87ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS
#88ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS
#89DESIGNED CYTOKINE COMPOSITIONS AND METHODS OF USE
#90Adenoviral Mediated Targeting of Activated Immune Cells
#91CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF
#92HUMAN INTERLEUKIN 2-POLYETHYLENE GLYCOL CONJUGATE AND USE THEREOF
#93TGF-Beta Polypeptides
#94ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents
#95THERAPEUTIC NUCLEIC ACID MOLECULE, MIXTURE, AND DRUG, AND USE THEREOF IN TREATING SOLID TUMOR
#96PHARMACEUTICAL COMPOSITION OF IL2 MUTANT-ANTIBODY FC BLOCK FUSION PROTEIN AND USE THEREOF
#97Split interleukin mimetics and their use
#98RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY
#99Antibodies and antibody fragments and analogues specific for chondroitin sulfate
#100INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
#101HUMAN INTERLEUKIN-2-DERIVED MUTEINS WITH SUPERAGONIST ACTIVITY
#102Synthetic Chromosome Encoding Two Or More Chimeric Antigen Receptors Binding To Tumor Associated Antigens
#103COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE TOLERANCE
#104DE NOVO DESIGN OF POTENT AND SELECTIVE INTERLEUKIN MIMETICS
#105INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
#106NOVEL INTERLEUKIN-2 POLYPEPTIDES
#107PROTEINS FOR MODULATING CELL THERAPY PRODUCTS AND METHODS OF USE THEREOF
#108CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS TARGETING EGFR SUPER-FAMILY RECEPTORS
#109IL-2 Conjugates and Methods of Use to Treat Autoimmune Diseases
#110METHOD FOR REALIZING CONTROLLED RELEASE AND SUSTAINED RELEASE OF ACTIVITY OF BIOACTIVE MOLECULES AND USE FOR DRUGS
#111IL-2 AND TL1A FUSION PROTEINS AND METHODS OF USE THEREOF
#112CYTOKINE FUSION PROTEIN
#113METHODS FOR MODULATING AN IMMUNE RESPONSE
#114NKp46-Binding Polypeptides and Uses Thereof
#115ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS
#116METHODS FOR MODULATING AN IMMUNE RESPONSE
#117DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10
#118NOVEL IMMUNOSTIMULATING VECTOR SYSTEM
#119NOVEL CYTOKINE PRODRUGS
#120VIRAL VECTORS AND PACKAGING CELL LINES
#121VIRAL VECTORS AND PACKAGING CELL LINES
#122INTERLEUKIN-2 MUTEINS, FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
#123T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#124FUSION PROTEIN OF INTERLEUKIN 2 AND APPLICATION THEREOF IN IBD
#125Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
#126PROTEIN FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF
#127MASKED IL-2 CYTOKINES AND METHODS OF USE THEREOF
#128MULTISPECIFIC MOLECULES BINDING TO TCR AND USES THEREOF
#129Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof
#130T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof
#131VHH MASKED CYTOKINES AND METHODS OF USE THEREOF
#132ENGINEERED IL-2 Fc FUSION PROTEINS
#133VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING THERAPEUTIC ANTI-IGF-1R ANTIBODIES AND METHODS OF USING THE SAME
#134SYSTEMS OF ENGINEERED RECEPTORS TARGETING PSMA AND CA9
#135COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES AND DISORDERS
#136MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#137Immunoconjugates
#138Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 Cells
#139COMPOSITIONS COMPRISING TRUNCATED INTERLEUKIN-33 AND INTERLEUKIN-2
#140ARTIFICIAL CELL DEATH POLYPEPTIDE FOR CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF
#141INTERLEUKIN-2 AGENTS AND USES THEREOF
#142RNA CONSTRUCT
#143ALTERING CYTOKINE SPECIFICITY THROUGH BINDING VALENCY
#144FUSION PROTEINS COMPOSED OF AN ANTIBODY AND A MUTEIN
#145METHODS AND COMPOSITIONS FOR NATURAL KILLER CELLS
#146METHODS TO GENERATE ENHANCED TUMOR INFILTRATING LYMPHOCYTES THROUGH MICROFLUIDIC DELIVERY
#147Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling
#148NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF
#149ENGINEERED SAFETY IN CELL THERAPY
#150KIDNEY TARGETED IMMUNOTOLERANCE
#151T-Cell Engaging Polypeptides and Methods of Use Thereof
#152SYNTHETIC CYTOKINE CIRCUITS TO PROMOTE INFILTRATION AND CLEARANCE OF IMMUNE EXCLUDED SOLID TUMORS BY ENGINEERED IMMUNE CELLS
#153Cell signaling complexes and uses thereof
#154Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling
#155MULTISPECIFIC ANTIBODIES BINDING TO CD20, NKP46, CD16 AND CONJUGATED TO IL-2
#156IL-2 VARIANTS AND FUSION PROTEINS THEREOF
#157Anti-pd-1 antibody-attenuated IL-2 immunoconjugates and uses thereof
#158IL-2 FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
#159Linker Polypeptides
#160CONDITIONALLY ACTIVATED IMMUNOCYTOKINES AND METHODS OF USE
#161FUSION PROTEIN COMPRISING ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOF
#162CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS
#163FUSION PROTEIN OF ANTI-TIGIT ANTIBODY AND IL2 OR VARIANT THEREOF AND APPLICATION THEREOF
#164NOVEL IL2 AGONISTS AND METHODS OF USE THEREOF
#165PARTIAL AGONISTS OF INTERLEUKIN-2, NUCLEIC ACIDS ENCODING THE SAME, AND METHODS OF USE THEREOF
#166MULTISPECIFIC PROTEINS BINDING TO NKP46, A CYTOKINE RECEPTOR, A TUMOUR ANTIGEN AND CD16A
#167IMMUNOMODULATORY MOLECULES AND USES THEREOF
#168APOLIPOPROTEIN FUSION PROTEINS FOR CELL-SPECIFIC IMMUNE REGULATION
#169INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND THEIR USES
#170INTERLEUKIN-2 MUTANT AND FUSION PROTEIN THEREOF
#171CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS
#172Use Of Growth Factors For T Cell Activation
#173NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
#174MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#175METHODS OF USING INTERLEUKIN-2 AGENTS
#176INTERLEUKIN 2 CHIMERIC CONSTRUCTS WITH TARGETING SPECIFICY TO INFLAMED TISSUES
#177PROTEASE-ACTIVATED POLYPEPTIDES
#178CONDITIONALLY ACTIVATED PROTEINS AND METHODS OF USE
#179COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY
#180BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS
#181IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
#182MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#183HUMAN INTERLEUKIN-2 VARIANT AND USE THEREOF
#184ANTI-PD-L1 AND IL-2 CYTOKINES
#185IMMUNOREGULATORY METHOD, NUCLEIC ACID COMPOSITION FOR IMMUNOREGULATION, AND USE THEREOF
#186FUSION PROTEIN OF INTERLEUKIN-2 AND APPLICATION THEREOF IN ALS
#187IMMUNOCONJUGATE MOLECULES AND RELATED METHODS AND COMPOSITIONS THEREOF
#188THERAPEUTIC MUTEINS
#189ANTIBODIES COMPRISING A POLYPEPTIDE INSERTED IN FRAMEWORK 3 REGION
#190CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY PLATFORM
#191SYNTHETIC IMMUNO-SUPPRESSIVE CELLS AND METHODS OF USE THEREOF
#192MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
#193MODULAR SYNTHETIC RECEPTORS AND METHODS OF USE
#194ENGINEERED SOLUBLE DECOY RECEPTORS TO ENHANCE CANCER IMMUNOTHERAPY
#195THERAPEUTIC RNA FOR TREATING CANCER
#196SYNTHETIC NUCLEIC ACID ELEMENTS FOR ENHANCING CAR T CELL EFFICACY
#197INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
#198INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
#199T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
#200ENGINEERED NATURAL KILLER (NK) CELLS AND RELATED METHODS
#201ANTI-CD25 ANTIBODY AGENTS
#202IL-2 MUTEINS FOR TREATING CANCER OR INFECTION
#203IMPROVED ADOPTIVE CELL TRANSFER THERAPY FOR CANCER
#204CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS
#205SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL DELIVERY OF ORTHOGONAL IL-2
#206MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
#207LONG-ACTING RECOMBINANT HUMAN INTERLEUKIN-2 FUSION PROTEIN, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
#208INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
#209PRECURSOR PROTEINS AND KIT FOR TARGETED THERAPY
#210COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATE AND ANTI-TYRP1/ANTI-CD3 BISPECIFIC ANTIBODIES
#211SKIN TARGETED IMMUNOTOLERANCE
#212ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF
#213FUNCTIONAL CELL-BASED POTENCY ASSAY FOR MEASURING BIOLOGICAL ACTIVITY OF INTERLEUKIN 2 (IL-2) ANALOGS
#214ATP-dependent agonists of immune cells function as anticancer agents
#215RECIPROCALLY MASKED ANTIBODY-CYTOKINE FUSION PROTEINS AND METHODS OF USE THEREOF
#216INTERLEUKIN-2 VARIANTS AND METHODS OF USES THEREOF
#217IL-2 mutant and application thereof
#218Interleukin-2 agents and uses thereof
#219IL-2 MUTEINS AND USES THEREOF
#220FULLY HUMAN ANTIBODY FOR HUMAN B7H3, CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF
#221ATTENUATED SALMONELLA GALLINARUM EXPRESSING FLIC OR FLIC-HIL2 AND USES THEREOF
#222IL-2 MUTEINS AND USES THEREOF
#223RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING
#224ANTIBODIES TARGETING BAFF-R AND USE THEREOF
#225COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS
#226PLATFORM TECHNOLOGY FOR TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL AND/OR AUTOIMMUNOLOGICAL DISEASES
#227IL-2 PROCYTOKINE ANTIBODY FUSION PROTEINS
#228ACTIVATABLE POLYPEPTIDE SEQUENCES FOR PREPARING CYCLIZED POLYPEPTIDES
#229Il-2 Mutant And Application Thereof
#230IL2 TETHERED TO ITS RECEPTOR IL2RBETA AND PORE-FORMING PROTEINS AS A PLATFORM TO ENHANCE IMMUNE CELL ACTIVITY
#231COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#232LIMITED SELF-REPLICATING MRNA MOLECULAR SYSTEM, PRODUCING METHOD AND USE
#233MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING
#234T-cell modulatory multimeric polypeptides and methods of use thereof
#235IL-2 BASED CONSTRUCTS
#236Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
#237NEW METHOD TO IMPROVE THE ANTI-TUMORAL ACTIVITY OF MACROPHAGES
#238IMMUNOCYTOKINES AND USES THEREOF
#239Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof
#240BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS
#241Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
#242NEW SCAFFOLD FOR BIFUNCTIONAL MOLECULES WITH IMPROVED PROPERTIES
#243MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
#244KINASE MUTANTS AND USES THEREOF
#245FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
#246ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF
#247METHODS FOR MODULATING AN IMMUNE RESPONSE
#248ANTI-ICOS ANTIBODIES
#249IMMUNE-STIMULATING IL-2 FUSION PROTEINS
#250MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF
#251ANTIBODY-CYTOKINS ENGRAFTED PROTEINS AND METHODS OF US IN THE TREATMENT OF CANCER
#252THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS
#253ENGINEERED CLEAVABLE CARRIERS AND METHODS OF USE THEREOF
#254T-cell modulatory multimeric polypeptides and methods of use thereof
#255Cytokine-based bioactivatable drugs and methods of uses thereof
#256PLATFORM TECHNOLOGY FOR TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL AND/OR AUTOIMMUNOLOGICAL DISEASES
#257BIFUNCTIONAL CYTOKINE COMPOSITIONS
#258COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES
#259METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES
#260IMMUNOSTIMULATORY CYTOKINE COMBINATION AND THERAPEUTIC USE THEREOF
#261An oncolytic virus vector coding for variant interleukin-2 (vIL-2) polypeptide
#262USE OF IL-2R-BETA-GAMMA AGONIST PEPTIDES IN CELL MANUFACTURING
#263HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
#264BI-FUNCTIONAL LINEAR FUSION COLLAGEN-LOCALIZED IMMUNOMODULATORY MOLECULES AND METHODS THEREOF
#265MHC CLASS II T-CELL MODULATORY POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
#266COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATES AND FAP/4-1BB BINDING MOLECULES
#267ENGINEERED PROTEINS TO ENHANCE SENSITIVITY OF A CELL TO IL-2
#268COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY
#269PH-DEPENDENT MUTANT INTERLEUKIN-2 POLYPEPTIDES
#270MEANS AND METHODS FOR REGULATING INTRACELLULAR TRAFFICKING OF SECRETORY OR CELL MEMBRANE-ANCHORED PROTEINS OF INTEREST
#271T-cell modulatory multimeric polypeptides and methods of use thereof
#272Cytokine conjugates for the treatment of proliferative and infectious diseases
#273T-cell modulatory multimeric polypeptides and methods of use thereof
#274ANTI-PD-1 ANTIBODY-ATTENUATED IL-2 IMMUNOCONJUGATES AND USES THEREOF
#275De novo design of potent and selective interleukin mimetics
#276LIGHT CHAIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE THEREOF
#277Dual cytokine fusion proteins comprising IL-10
#278Dual cytokine fusion proteins comprising IL-10
#279Dual cytokine fusion proteins comprising IL-10
#280Dual cytokine fusion proteins comprising IL-10
#281Dual cytokine fusion proteins comprising IL-10
#282Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies
#283Fusion Protein of Human Serum Albumin and Interleukin-2, and Use Thereof
#284T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#285Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
#286INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF
#287Dual cytokine fusion proteins comprising IL-10
#288Dual cytokine fusion proteins comprising IL-10
#289Interleukin-2 variants and methods of uses thereof
#290Dual cytokine fusion proteins comprising IL-10
#291Dual cytokine fusion proteins comprising IL-10
#292Dual cytokine fusion proteins comprising IL-10
#293IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
#294IL-2 MUTEINS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES
#295TARGETED CYTOKINE CONSTRUCT FOR ENGINEERED CELL THERAPY
#296Cytokine Prodrugs Comprising a Cleavable Linker
#297INTERLEUKIN-21 MUTANT AND USE THEREOF
#298PROTEIN CONTAINING HETERODIMER ANTIBODY FC, AND PREPARATION METHOD THEREFOR
#299T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
#300IL-2 MUTANT PROTEIN AND MEDICINE CONTAINING SAME